Where the stock stands
Anthem Biosciences Ltd., a Healthcare company, last traded at ₹923.05, up 5.53% from its previous close of ₹874.70. With a market capitalisation of ₹50,779 crore, it trades at a price-to-earnings multiple of 88.98 and a price-to-book multiple of 16.69, carrying a thin dividend yield of 0.22%. The stock sits just 3.24% below its 52-week high of ₹904.00 and 51.03% above its 52-week low of ₹579.15.
What the smart-money flow shows
The recorded deals cluster on a single day, 2026-06-18, and are large. ARUNA GANESH sold shares worth ₹1,274.70 crore — recorded twice at that value — while a slate of institutions bought on the other side: HDFC Mutual Fund and Kotak Mahindra Mutual Fund took ₹100 crore each, Bajaj Life and ICICI Prudential Life took ₹90 crore each, SBI Mutual Fund ₹80.29 crore and Prudential Hong Kong ₹76 crore. The data shows a June sale by one holder distributed into several institutional books, with no F&O positioning or insider-filing detail supplied.
The technical picture
The stock is above both its 50-day and 200-day simple moving averages, a constructive setup, with no golden or death cross flagged. It has gained 10.64% over the past month and 15.51% over the past three months, though it slipped 1.83% over the past week; on a one-year view it is up 3.34%. The 14-day relative strength index is 61.6 and relative volume is 0.5, meaning the latest session was quieter than average even as the price rose.
Catalysts and what to watch
The pack carries no exchange-filing catalysts for the stock, so the watch items come from the news and the flow. Headlines describe the stock touching a fresh 52-week high and a June-quarter result where shares fell over 7% on delayed-delivery pressure, alongside a broker (PL Capital) staying bullish. The data does not establish a single driver for the move; what it shows is a richly valued healthcare name near its highs, with a June block distribution into institutions and a near-term test of whether the earnings delivery keeps pace with the price.